Sino Biological Recombinant Omicron BA5 and BA4 Antigens

Canadian Approval for Xpert™ MRSA Test and GeneXpert® System

Cepheid has announced that Health Canada has issued a medical device license for the Xpert™ MRSA test for the rapid detection of Methicillin Resistant Staphylococcus aureus (MRSA) on nasal swabs and the GeneXpert® System.

The license enables access to the Canadian HAI Market; market expenditures for MRSA surveillance are expected to reach $80 million by 2012.

Xpert MRSA test results are available in approximately 70 minutes thereby enabling rapid identification of carriers of the potential pathogen in less than two hours, from the acquisition of the patient sample to returning the result to the floor.

The availability of the Xpert MRSA test and the GeneXpert System is expected to help enable Canadian healthcare organizations to implement more efficient infection control measures, leading to lower hospital acquired infection rates and improved patient care.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Cepheid View Company Information

Posted on February 1, 2008